Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors
The year 2021 -- that's when Gilead Sciences (NASDAQ: GILD) thinks its acquisition of Kite Pharma (NASDAQ: KITE) will start to pay off. When Gilead announced plans to buy Kite, the company stated that the deal was expected to be neutral to earnings by year three and accretive after that.
In one sense, though, Gilead's Kite Pharma acquisition has already paid for itself. How? For investors.
Image source: Getty Images.
Source: Fool.com
Sanofi S.A. ADR Aktie
49,40 €
1,23 %
Positive Tendenz für Sanofi S.A. ADR mit mehreren Buy- und keiner Sell-Einschätzung.
Mit einem Kursziel von 55 € für Sanofi S.A. ADR ist ein leichter Anstieg gegenüber dem aktuellen Kurs von 49.4 € zu erwarten.
